Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 42,000 Shares of Stock

Key Points

• Eben Tessari, COO of Kiniksa Pharmaceuticals International, sold 42,000 shares at an average price of $38.33, totaling approximately $1.61 million, reducing his ownership by 54.86%.
• Following the latest sale, Tessari owns 34,552 shares, valued at about $1.32 million, signaling a significant decrease in his stake in the company.
• Kiniksa Pharmaceuticals reported a net margin of 0.90% and a revenue of $156.80 million for the last quarter, exceeding analysts' expectations.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 42,000 shares of the firm's stock in a transaction on Monday, September 29th. The shares were sold at an average price of $38.33, for a total transaction of $1,609,860.00. Following the transaction, the chief operating officer directly owned 34,552 shares of the company's stock, valued at $1,324,378.16. The trade was a 54.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Eben Tessari also recently made the following trade(s):

• On Monday, September 15th, Eben Tessari sold 16,400 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $36.46, for a total transaction of $597,944.00.
• On Thursday, September 4th, Eben Tessari sold 85,271 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.52, for a total transaction of $3,028,825.92.
• On Friday, September 5th, Eben Tessari sold 13,389 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.66, for a total transaction of $477,451.74.
• On Wednesday, September 3rd, Eben Tessari sold 15,091 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.50, for a total transaction of $535,730.50.
• On Monday, August 18th, Eben Tessari sold 16,200 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $33.77, for a total transaction of $547,074.00.
• On Tuesday, August 5th, Eben Tessari sold 138,614 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $33.20, for a total transaction of $4,601,984.80.
• On Monday, July 14th, Eben Tessari sold 18,900 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $28.72, for a total transaction of $542,808.00.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA traded down $0.19 on Wednesday, reaching $38.64. The company's stock had a trading volume of 447,105 shares, compared to its average volume of 648,549. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $39.12. The company has a market cap of $2.86 billion, a P/E ratio of 966.24 and a beta of 0.20. The company has a 50-day simple moving average of $33.80 and a 200 day simple moving average of $28.38.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The business had revenue of $156.80 million during the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nuveen LLC purchased a new position in shares of Kiniksa Pharmaceuticals International during the first quarter worth approximately $16,992,000. Arrowstreet Capital Limited Partnership bought a new position in Kiniksa Pharmaceuticals International in the second quarter worth approximately $20,349,000. Qube Research & Technologies Ltd raised its position in Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company's stock valued at $24,581,000 after purchasing an additional 653,236 shares in the last quarter. Acadian Asset Management LLC raised its position in Kiniksa Pharmaceuticals International by 170.3% during the 1st quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock valued at $22,961,000 after purchasing an additional 651,700 shares in the last quarter. Finally, Rubric Capital Management LP lifted its holdings in shares of Kiniksa Pharmaceuticals International by 15.6% in the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company's stock worth $108,184,000 after buying an additional 526,567 shares during the period. Institutional investors own 53.95% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. TD Cowen assumed coverage on shares of Kiniksa Pharmaceuticals International in a research note on Monday. They issued a "buy" rating and a $60.00 price objective for the company. Wedbush reissued an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Sunday, September 7th. Wells Fargo & Company raised their target price on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an "overweight" rating in a report on Thursday, September 25th. Finally, Jefferies Financial Group raised their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Seven equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $44.29.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.